Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures: 2021-2025

Historic Capital Expenditures for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $1.7 million.

  • Krystal Biotech's Capital Expenditures rose 717.39% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 11.45%. This contributed to the annual value of $8.5 million for FY2024, which is 27.99% down from last year.
  • Latest data reveals that Krystal Biotech reported Capital Expenditures of $1.7 million as of Q3 2025, which was down 10.50% from $1.9 million recorded in Q2 2025.
  • Krystal Biotech's Capital Expenditures' 5-year high stood at $40.9 million during Q4 2021, with a 5-year trough of -$867,000 in Q2 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $696,000 (2023), whereas its average is $2.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 362.86% in 2024, then skyrocketed by 1,600.00% in 2025.
  • Quarterly analysis of 5 years shows Krystal Biotech's Capital Expenditures stood at $40.9 million in 2021, then plummeted by 87.24% to $5.2 million in 2022, then tumbled by 86.66% to $696,000 in 2023, then plummeted by 70.55% to $205,000 in 2024, then surged by 717.39% to $1.7 million in 2025.
  • Its Capital Expenditures stands at $1.7 million for Q3 2025, versus $1.9 million for Q2 2025 and $6.2 million for Q1 2025.